Rola winpocetyny w zapobieganiu zaburzeniom funkcji poznawczych u pacjentów z nadciśnieniem tętniczym Artykuł przeglądowy
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
gru 31, 2014
Słowa kluczowe:
nadciśnienie tętnicze, zaburzenia funkcji poznawczych, winpocetyna, choroba Alzheimera, otępienie naczyniowe
##plugins.themes.bootstrap3.article.main##
Abstrakt
Zmiany otępienne są coraz częstszym problemem w polskim społeczeństwie. Zarówno w badaniach epidemiologicznych, jak i prospektywnych wykazano, że wieloletnie nadciśnienie tętnicze może prowadzić do upośledzenia funkcji poznawczych i rozwoju objawów otępiennych. Na podstawie dotychczasowych badań można przypuszczać, że skuteczna terapia hipotensyjna istotnie zmniejsza ryzyko wystąpienia tych zmian u chorych z nadciśnieniem tętniczym. Jednocześnie należy podkreślić, że zaburzenia funkcji poznawczych, które współwystępują z nadciśnieniem tętniczym, mogą istotnie pogarszać współpracę z pacjentem, czyniąc terapię hipotensyjną nieskuteczną i zwiększając ryzyko wielu powikłań. Ważną rolę w terapii takiego chorego może odegrać winpocetyna, powodująca poprawę w zakresie funkcji poznawczych.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Barylski , M., & Rosołowska, A. (2014). Rola winpocetyny w zapobieganiu zaburzeniom funkcji poznawczych u pacjentów z nadciśnieniem tętniczym. Medycyna Faktów , 7(4(25), 58-66. Pobrano z https://journalsmededu.pl/index.php/jebm/article/view/2338
Numer
Dział
Artykuły
Copyright © by Medical Education. All rights reserved.
Bibliografia
1. Johnston S.V., O’Meara E.S., Manolio T.A. et al.: Cognitive impairment and decline are associated with carotid artery disease in patients without clinically evident cerebrovascular disease. Ann. Intern. Med. 2004; 140: 237-247.
2. Kilander L., Nyman H., Boberg M. et al.: Hypertension is related to cognitive impairment: a 20-year follow-up study of 999 men. Hypertension 1998; 31: 780-786.
3. Skoog I., Lernfelt B., Landahl S.: Fitteen-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-1145.
4. Elias M.E., Wolf P.A., D’Agostino R.B.: Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am. J. Epidemiol. 1993; 138: 353-364.
5. Tzourio C., Dufouil C., Ducimetiere P. et al.: Cognitive decline in individuals with high blood pressure. Neurology 1999; 53: 1948-1952.
6. Launer L.J., Masaki K., Petrovitch H. i wsp.: The association between midlife blood pressure levels and late-life cognitive function. The Honolulu – Asia Aging Study. JAMA 2004; 292: 2237-2242.
7. Elias P.K., Elias M.F., Robbins M.A. et al.: Blood pressure-related cognitive decline: does age make a difference? Hypertension 2004; 44: 631-636.
8. Suhr J.A., Stewart J.C., France C.R.: The relationship between blood pressure and cognitive performance in the Third National Health and Nutrition Examination Survery (NHANES III). Psychosom. Med. 2004; 66: 291-297.
9. Kuo H.K., Yen C.J., Chang C.H. et al.: Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol. 2005; 4(6): 371-380.
10. Bellew K.M., Pigeon J.G., Stang P.E. et al.: Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Dis. Assoc. Disord. 2004; 18(4): 208-213.
11. Launer L.J., Masaki K., Petrovitch H. et al.: The association between midlife blood pressure levels and late-life cognitive function. JAMA 1995; 274: 1846-1851.
12. Launer L.J., Ross G.W., Petrovitch H. et al.: Midlife blood pressure levels and dementia: the Honolulu-Asia aging study. Neurobiol. Aging 2000; 21: 49-55.
13. Jennings J.R.: Autoregulation of blood pressure and thought: preliminary results of an application of brain amaging to psychosomatic medicine. Psychosom. Med. 2003; 65: 384-395.
14. Mulvany M.J.: Small aorty remodeling and significance in the development of hypertension. New Physiol. Sci. 2002; 17: 105-109.
15. Manolio T.A., Olson J., Longstreth W.T.: Nadciśnienie tętnicze a funkcje poznawcze: patofizjologiczny wpływ nadciśnienia tętniczego na mózg. Medycyna po Dyplomie 2004; 13(15): 88-98.
16. van Dijk W.J., Breteler M.M.B., Schmidt R. et al.; CASCADE Consortium: The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study. Hypertension 2004; 44: 625-630.
17. Majeski E.I., Widener C.E., Basile J.: Hypertension and dementia: does blood pressure control favorably affect cognition? Curr. Hypertens. Rep. 2004; 6: 357-362.
18. Di Bari M., Pahor M., Franse L.V.: Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in elderly program (SHEP) trial. Am. J. Epidemiol. 2001; 153: 72-78.
19. Forette F., Seux M.I., Staessen J.A.: The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) Study. Arch. Intern. Med. 2002; 162: 2046-2052.
20. Lithell H., Hansson L., Skoog I. et al.: The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J. Hypertens. 2004; 22: 1605-1612.
21. Lithell H., Hansson L., Skoog I.: The Study on COgnition and Prognosis in the Elderly (SCOPE); principal results of a randomized double-blind intervention trial. J. Hypertens. 2003; 21: 875-886.
22. Feigin V., Ratnasabapathy Y., Anderson C.: Does blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? J. Neurol. Sci. 2005; 229-230: 151-155.
23. McGuinness B., Todd S., Passmore P.: The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst. Rev. 2006; 2, CD004034.
24. Birkenhäger W.H., Staessen J.A.: Progress in cardiovascular diseases: cognitive function in essential hypertension. Prog. Cardiovascular Dis. 2006; 49: 1-10.
25. Birns J., Morris R., Donaldson N. et al.: The effects of blood pressure reduction on cognitive function: a review of effects based on pooled data from clinical trials. J. Hypertens. 2006; 24: 1907-1914.
26. Guo Z., Fratiglioni L., Zhu L. et al.: Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch. Neurol. 1999; 56: 991-996.
27. Hagstrom B., Mattsson B., Rost I.M. et al.: What happened to the prescriptions? A single, short, standardized telephone call may increase compliance. Fam. Pract. 2004; 21: 46-50.
28. Grodzicki T., Gryglewski R., Tomasik T. et al.: Zasady postępowania w nadciśnieniu tętniczym w wieku podeszłym. Wytyczne Kolegium Lekarzy Rodzinnych w Polsce, Polskiego Towarzystwa Nadciśnienia Tętniczego, Polskiego Towarzystwa Gerontologicznego. Gerontol. Pol. 2012; 20(4): 119-147.
29. Manconi E., Binaghi F., Pitzus F.: A double-blind clinical trial of vinpocetine in the treatment of cerebral insuficiency of vascular and degenerative origin. Curr. Ther. Res. 1986; 40: 702-712.
30. Reisberg B., Ferris S.H., Shulman E. et al.: Longitudinal course on normal ageing and progressive dementia of Alzheimer’s type: a prospective study of 106 subject over a 3,6 year mean interval. Prog. Neuro-Psychopharmacol. Psychiatry 1986; 10: 571-578.
31. Reisberg B., Ferris S.H., de Leon M.J. et al.: Stage specific behavioral cognitive, and in vivo changes in community residing subjects with age associated memory impairment and primary degenerative dementia of Alzheimer type. Drug Develop. Res. 1988; 15: 101-114.
32. Petersen R.C., Doody R., Kurz A. et al.: Current concepts in mild cognitive impairment. Arch. Neurol. 2001; 58: 1985-1992.
33. Petersen R.C., Smith G.E., Waring S.C. et al.: Mild cognitive impairment: clinical characterization an outcome. Arch. Neurol. 1999; 56: 303-308.
34. Winblad B., Palmer K., Kipivelto M. et al.: Mild cognitive impairment – beyond controversies, towards a consensus: report of International Working Group on Mild Cognitive Impairment. J. Intern. Med. 2004; 256: 240-246.
35. Mitchell A.J., Shiri Feshki M.: Rate of progression of mild cognitive impairment to dementia – meta-analysis of 41 robust inception cohort studies. Acta Psychiatr. Scand. 2009; 119: 252-265.
36. Krasuski J.S., Alexander G.E., Horwitz B.: Volumes of medial temporal lobe structures in patiens with Alzheimer’s disease and mild cognitive impairment. Biol. Psychiatry 1998; 43: 60-68.
37. Callahan M., Hendrie H.C., Tierny W.M.: Documentation and evaluation of cognitive impairment in elderly primary care patiens. Ann. Intern. Med. 1995; 122: 422-429.
38. Gabryelewicz T., Styczyńska M., Łuczywek E. et al.: The rate conversion of mild cognitive impairment to dementia: predictive role of depression. Int. J. Geriatr. Psychiatry 2007; 22: 563-567.
39. Jack C.R., Petersen R.C., Xu Y. Warring S.C. et al.: Medial temporal atrophy on MRI in normal aging and very mild Alzheimer’s disease. Neurology 1997; 49: 786-794.
40. Nicholson C.D.: Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology 1990; 101: 147-159.
41. Bönöczk P., Gulyás B., Adam-Vizi V. et al.: Role of sodium chanel inhibition in neuroprotection: effect of vinpocetine. Brain Res. Bull. 2000; 3: 245-254.
42. Szatmari S.Z., Whitehouse P.J.: Vinpocetine for cognitive impairment and dementia. The Cochrane Database of Systematic Reviews 2003, Issue 1.
43. Jacobs J.D., Bernhard M.R., Delgado A. et al.: Screening for organic mental syndromes in the medically ill. Ann. Intern. Med. 1977; 86: 40-48.
2. Kilander L., Nyman H., Boberg M. et al.: Hypertension is related to cognitive impairment: a 20-year follow-up study of 999 men. Hypertension 1998; 31: 780-786.
3. Skoog I., Lernfelt B., Landahl S.: Fitteen-year longitudinal study of blood pressure and dementia. Lancet 1996; 347: 1141-1145.
4. Elias M.E., Wolf P.A., D’Agostino R.B.: Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study. Am. J. Epidemiol. 1993; 138: 353-364.
5. Tzourio C., Dufouil C., Ducimetiere P. et al.: Cognitive decline in individuals with high blood pressure. Neurology 1999; 53: 1948-1952.
6. Launer L.J., Masaki K., Petrovitch H. i wsp.: The association between midlife blood pressure levels and late-life cognitive function. The Honolulu – Asia Aging Study. JAMA 2004; 292: 2237-2242.
7. Elias P.K., Elias M.F., Robbins M.A. et al.: Blood pressure-related cognitive decline: does age make a difference? Hypertension 2004; 44: 631-636.
8. Suhr J.A., Stewart J.C., France C.R.: The relationship between blood pressure and cognitive performance in the Third National Health and Nutrition Examination Survery (NHANES III). Psychosom. Med. 2004; 66: 291-297.
9. Kuo H.K., Yen C.J., Chang C.H. et al.: Relation of C-reactive protein to stroke, cognitive disorders, and depression in the general population: systematic review and meta-analysis. Lancet Neurol. 2005; 4(6): 371-380.
10. Bellew K.M., Pigeon J.G., Stang P.E. et al.: Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type. Dis. Assoc. Disord. 2004; 18(4): 208-213.
11. Launer L.J., Masaki K., Petrovitch H. et al.: The association between midlife blood pressure levels and late-life cognitive function. JAMA 1995; 274: 1846-1851.
12. Launer L.J., Ross G.W., Petrovitch H. et al.: Midlife blood pressure levels and dementia: the Honolulu-Asia aging study. Neurobiol. Aging 2000; 21: 49-55.
13. Jennings J.R.: Autoregulation of blood pressure and thought: preliminary results of an application of brain amaging to psychosomatic medicine. Psychosom. Med. 2003; 65: 384-395.
14. Mulvany M.J.: Small aorty remodeling and significance in the development of hypertension. New Physiol. Sci. 2002; 17: 105-109.
15. Manolio T.A., Olson J., Longstreth W.T.: Nadciśnienie tętnicze a funkcje poznawcze: patofizjologiczny wpływ nadciśnienia tętniczego na mózg. Medycyna po Dyplomie 2004; 13(15): 88-98.
16. van Dijk W.J., Breteler M.M.B., Schmidt R. et al.; CASCADE Consortium: The association between blood pressure, hypertension, and cerebral white matter lesions: cardiovascular determinants of dementia study. Hypertension 2004; 44: 625-630.
17. Majeski E.I., Widener C.E., Basile J.: Hypertension and dementia: does blood pressure control favorably affect cognition? Curr. Hypertens. Rep. 2004; 6: 357-362.
18. Di Bari M., Pahor M., Franse L.V.: Dementia and disability outcomes in large hypertension trials: lessons learned from the systolic hypertension in elderly program (SHEP) trial. Am. J. Epidemiol. 2001; 153: 72-78.
19. Forette F., Seux M.I., Staessen J.A.: The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) Study. Arch. Intern. Med. 2002; 162: 2046-2052.
20. Lithell H., Hansson L., Skoog I. et al.: The Study on COgnition and Prognosis in the Elderly (SCOPE); outcomes in patients not receiving add-on therapy after randomization. J. Hypertens. 2004; 22: 1605-1612.
21. Lithell H., Hansson L., Skoog I.: The Study on COgnition and Prognosis in the Elderly (SCOPE); principal results of a randomized double-blind intervention trial. J. Hypertens. 2003; 21: 875-886.
22. Feigin V., Ratnasabapathy Y., Anderson C.: Does blood pressure lowering treatment prevents dementia or cognitive decline in patients with cardiovascular and cerebrovascular disease? J. Neurol. Sci. 2005; 229-230: 151-155.
23. McGuinness B., Todd S., Passmore P.: The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease. Cochrane Database Syst. Rev. 2006; 2, CD004034.
24. Birkenhäger W.H., Staessen J.A.: Progress in cardiovascular diseases: cognitive function in essential hypertension. Prog. Cardiovascular Dis. 2006; 49: 1-10.
25. Birns J., Morris R., Donaldson N. et al.: The effects of blood pressure reduction on cognitive function: a review of effects based on pooled data from clinical trials. J. Hypertens. 2006; 24: 1907-1914.
26. Guo Z., Fratiglioni L., Zhu L. et al.: Occurrence and progression of dementia in a community population aged 75 years and older: relationship of antihypertensive medication use. Arch. Neurol. 1999; 56: 991-996.
27. Hagstrom B., Mattsson B., Rost I.M. et al.: What happened to the prescriptions? A single, short, standardized telephone call may increase compliance. Fam. Pract. 2004; 21: 46-50.
28. Grodzicki T., Gryglewski R., Tomasik T. et al.: Zasady postępowania w nadciśnieniu tętniczym w wieku podeszłym. Wytyczne Kolegium Lekarzy Rodzinnych w Polsce, Polskiego Towarzystwa Nadciśnienia Tętniczego, Polskiego Towarzystwa Gerontologicznego. Gerontol. Pol. 2012; 20(4): 119-147.
29. Manconi E., Binaghi F., Pitzus F.: A double-blind clinical trial of vinpocetine in the treatment of cerebral insuficiency of vascular and degenerative origin. Curr. Ther. Res. 1986; 40: 702-712.
30. Reisberg B., Ferris S.H., Shulman E. et al.: Longitudinal course on normal ageing and progressive dementia of Alzheimer’s type: a prospective study of 106 subject over a 3,6 year mean interval. Prog. Neuro-Psychopharmacol. Psychiatry 1986; 10: 571-578.
31. Reisberg B., Ferris S.H., de Leon M.J. et al.: Stage specific behavioral cognitive, and in vivo changes in community residing subjects with age associated memory impairment and primary degenerative dementia of Alzheimer type. Drug Develop. Res. 1988; 15: 101-114.
32. Petersen R.C., Doody R., Kurz A. et al.: Current concepts in mild cognitive impairment. Arch. Neurol. 2001; 58: 1985-1992.
33. Petersen R.C., Smith G.E., Waring S.C. et al.: Mild cognitive impairment: clinical characterization an outcome. Arch. Neurol. 1999; 56: 303-308.
34. Winblad B., Palmer K., Kipivelto M. et al.: Mild cognitive impairment – beyond controversies, towards a consensus: report of International Working Group on Mild Cognitive Impairment. J. Intern. Med. 2004; 256: 240-246.
35. Mitchell A.J., Shiri Feshki M.: Rate of progression of mild cognitive impairment to dementia – meta-analysis of 41 robust inception cohort studies. Acta Psychiatr. Scand. 2009; 119: 252-265.
36. Krasuski J.S., Alexander G.E., Horwitz B.: Volumes of medial temporal lobe structures in patiens with Alzheimer’s disease and mild cognitive impairment. Biol. Psychiatry 1998; 43: 60-68.
37. Callahan M., Hendrie H.C., Tierny W.M.: Documentation and evaluation of cognitive impairment in elderly primary care patiens. Ann. Intern. Med. 1995; 122: 422-429.
38. Gabryelewicz T., Styczyńska M., Łuczywek E. et al.: The rate conversion of mild cognitive impairment to dementia: predictive role of depression. Int. J. Geriatr. Psychiatry 2007; 22: 563-567.
39. Jack C.R., Petersen R.C., Xu Y. Warring S.C. et al.: Medial temporal atrophy on MRI in normal aging and very mild Alzheimer’s disease. Neurology 1997; 49: 786-794.
40. Nicholson C.D.: Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology 1990; 101: 147-159.
41. Bönöczk P., Gulyás B., Adam-Vizi V. et al.: Role of sodium chanel inhibition in neuroprotection: effect of vinpocetine. Brain Res. Bull. 2000; 3: 245-254.
42. Szatmari S.Z., Whitehouse P.J.: Vinpocetine for cognitive impairment and dementia. The Cochrane Database of Systematic Reviews 2003, Issue 1.
43. Jacobs J.D., Bernhard M.R., Delgado A. et al.: Screening for organic mental syndromes in the medically ill. Ann. Intern. Med. 1977; 86: 40-48.